Hydroxyprogesterone oral - Lipocine

Drug Profile

Hydroxyprogesterone oral - Lipocine

Alternative Names: Hydroxyprogesterone caproate - Lipocine; LPCN-1107; Oral hydroxyprogesterone caproate - Lipocine

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lipocine
  • Class Hormones; Pregnenediones; Progesterone congeners; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preterm labour
  • New Molecular Entity No

Highest Development Phases

  • Phase II Preterm labour

Most Recent Events

  • 06 Sep 2017 Hydroxyprogesterone oral is still in phase I/II trials for Preterm labour (Prevention) in USA
  • 06 Mar 2017 Lipocine plans to initiate a phase III trial for Preterm labour (Prevention) in H1 2017
  • 06 Mar 2017 Lipocine announces intention to submit protocol for phase III study to US FDA through Special Protocol Assessment (SPA) for Preterm labour (Prevention) in 1H 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top